ARS Pharmaceuticals (SPRY) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 24, 2026, to be held virtually for shareholders of record as of April 27, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of three Class III director nominees to serve three-year terms until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes.

• Board recommends voting for all proposals and holding say-on-pay votes every year.

• Provision to conduct any other business properly brought before the meeting.

Board of directors and corporate governance

• Nominees for Class III director are Saqib Islam, J.D., Phillip Schneider, and Laura Shawver, Ph.D.